Biomarcadores/metabolismo; Insuficiencia Cardíaca/diagnóstico; Animales; Insuficiencia Cardíaca/metabolismo; Humanos

ADHERE; ADM; ANP; AUC; Acute Decompensated Heart Failure National Registry; Adrenomedullin; Area under the curve; Atrial natriuretic peptide; B-type natriuretic peptide; BACH; BNP; Biomarker; Biomarkers in Acute Heart Failure; CI; CORONA; Confidence interval; Controlled Rosuvastatin Multinational Trial in Heart Failure; Diagnosis; GDF-15; GISSI-HF; Growth differentiation factor-15; Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca­Heart Failure; HF; HF with preserved left ventricular ejection fraction; HFpEF; HR; Hazard ratio; Heart failure; Highly sensitive troponin; Highly sensitive troponin I; Highly sensitive troponin T; ICON; International Collaborative of NT-proBNP; LVSD; Left ventricular systolic dysfunction; MI; MR-proADM; MR-proANP; Management; Mid-regional pro adrenomedullin; Mid-regional pro atrial natriuretic peptide; Myocardial infarction; N-terminal pro B-type natriuretic peptide; NHANES; NT-proBNP; NYHA; National Health and Nutrition Examination Survey; New York Heart Association; PRIDE; ProBNP Investigation of Dyspnea in the Emergency Department; Prognosis; ST2 ligand; ST2L; Soluble ST2; Val-HeFT; Valsartan Heart Failure Trial; hsTn; hsTnI; hsTnT; sST2